Mediastinal small cell cancer associated with Lambert-Eaton myasthenic syndrome: A case report
- Authors:
- Kejian Zhang
- Wei Liu
- Yang Li
- Kewei Zhang
- Xinliang Gao
- Jing Wang
View Affiliations
Affiliations: Department of General Thoracic Surgery, Bethune Chest Center, Bethune First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
- Published online on: April 27, 2015 https://doi.org/10.3892/etm.2015.2454
-
Pages:
117-120
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Lambert-Eaton myasthenic syndrome (LEMS) is typically characterized as a paraneoplastic syndrome associated with small cell lung carcinoma. The presence of LEMS in association with other neuroendocrine lung tumors, including carcinoids or large cell lung carcinoma, is highly unusual. The present case study reports the very rare case of a patient with mediastinal small cell cancer combined with LEMS. A 53‑year‑old man was admitted to the Bethune First Hospital with a 3‑month history of weakness in the lower extremities that had become aggravated during the previous 20 days. A positron emission tomography‑computed tomography (CT) examination demonstrated multiple enlarged, hypermetabolic lymph nodes between the vena cava and trachea, indicating the presence of inflammation. No other abnormalities were identified. A mediastinal lymph node biopsy revealed a high prevalence of small cell neuroendocrine carcinoma. The immunohistochemistry results were as follows: Ki‑67 (+50, meaning that 50% of the cells exhibited Ki‑67 expression), cytokeratin (CK; +), cluster of differentiation (CD)56 (+), synaptophysin (+), thyroid transcriptional factor‑1 (+), epithelial membrane antigen (+), neuron‑specific enolase (+), P63 (weakly +), leukocyte common antigen (‑), CD99 (‑), vimentin (‑) and CK5/6 (‑). Following a diagnosis of LEMS, the patient underwent one course of cisplatin + etoposide chemotherapy, which was ineffective. Subsequently, the patient underwent a different chemotherapy regimen (cisplatin + etoposide + ifosfamide), which significantly improved the symptoms of myasthenia. Following completion of this treatment regimen, the primary lesion was not observed on a lung CT scan, and the mediastinal lymph nodes had clearly diminished. Subsequently, the patient underwent two courses of radiotherapy (40 Gy/22f/6W).
View References
|
1
|
Lee JH, Shin JH, Kim DS, et al: A case of
Lambert-Eaton myasthenic syndrome associated with atypical
bronchopulmonary carcinoid tumor. J Korean Med Sci. 19:753–755.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gilhus NE: Myasthenia and the
neuromuscular junction. Curr Opin Neurol. 25:523–529. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tomiyasu K, Ito H, Kanazawa N, Saito T and
Kowa H: Anti-Hu antibody in a patient with Lambert-Eaton myasthenic
syndrome and early detection of small cell lung cancer. Intern Med.
34:1082–1085. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
LoMonaco M, Milone M, Padua L and Tonali
P: Combined low-rate nerve stimulation and maximal voluntary
contraction in the detection of compound muscle action potential
facilitation in Lambert-Eaton myasthenic syndrome. Muscle Nerve.
20:1207–1208. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Titulaer MJ, Lang B and Verschuuren JJ:
Lambert-Eaton myasthenic syndrome: from clinical characteristics to
therapeutic strategies. Lancet Neurol. 10:1098–1107. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martín-García E, Mannara F,
Gutiérrez-Cuesta J, et al: Intrathecal injection of P/Q type
voltage-gated calcium channel antibodies from paraneoplastic
cerebellar degeneration cause ataxia in mice. J Neuroimmunol.
261:53–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu X, Wang J, Liu Y and Liu K: Clinical
presentation and differential diagnosis of Lambert-Eaton myasthenic
syndrome. Neurosciences (Riyadh). 18:169–172. 2013.PubMed/NCBI
|
|
8
|
Nakamur S, Kawagishi Y, Kato S, et al:
Long-term survival case of small-cell lung cancer with
Lambert-Eaton myasthenic syndrome without anticancer therapy. Nihon
Kokyuki Gakkai Zasshi. 48:918–922. 2010.(In Japanese). PubMed/NCBI
|
|
9
|
Baggi F, Ubiali F, Nava S, et al: Effect
of IgG immunoadsorption on serum cytokines in MG and LEMS patients.
J Neuroimmunol. 201–202:104–110. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsukiji J, Kaneko T, Saito H, et al: A
case of cT0N2M0 small cell lung cancer with Lambert-Eaton
myasthenic syndrome. Nihon Kokyuki Gakkai Zasshi. 42:820–824.
2004.(In Japanese). PubMed/NCBI
|
|
11
|
Oh SJ, Kurokawa K, Claussen GC and Ryan HF
Jr: Electrophysiological diagnostic criteria of Lambert-Eaton
myasthenic syndrome. Muscle Nerve. 32:515–520. 2005. View Article : Google Scholar : PubMed/NCBI
|
